Global Hepatitis C Treatment Market : Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Hepatitis C is an irresistible infection caused by Hepatitis C infection (HCV) and influences essentially the liver. Hepatitis C is normally caused by blood to blood contacts, for example, intravenous medication utilize, unsterilized hardware, blood transfusions, and ***. Hepatitis C may likewise cause from mother to embryo amid birth. Individuals with liquor abuse and HIV disease of all ages assemble are at expanded hazard. As of now, there is no immunization accessible to treat hepatitis C conditions. In any case, different medications, for example, protease inhibitors, HCV polymerase inhibitors, and HCV NS5A inhibitors are normally used to treat Hepatitis C. Beginning time of contamination regularly has no side effects. The basic phase of contamination may show indications, for example, fever, dull pee, stomach agony, and yellow-tinged skin event. The seriousness in hepatitis C may prompt liver cirrhosis, liver disease, liver disappointment, and now and again likewise causes the widened veins in the throat and stomach. Hepatitis C can be averted by utilizing disinfected hardware, screening of blood givers, keeping away from numerous sexual accomplices, and abstaining from sharing of infusions and razors.
The global market for Hepatitis C treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis C infection. Rising awareness regarding Hepatitis C treatment, increase in healthcare expenditure, and government initiatives and various NGO’s creating awareness regarding the Hepatitis C treatment is expected to fuel the market growth over the forecast period. In addition, rise in the funding in research and development activities for Hepatitis C treatment and strong pipeline products might boost the global Hepatitis C treatment market over the forecast period. However, lack of antibiotics in the market, high cost of medications, and lack of hepatitis C infection awareness in poor countries might hamper the growth of global Hepatitis C treatment market over the forecast period.
A sample of this report is available upon request @
Hepatitis C treatment market segmented on the basis of drug class, route of administration, and distribution channel
Based on drug class, the hepatitis C treatment market has been segmented into the following:
• Polymerase Inhibitors
• NS5A Inhibitors
• Interferons
• HCV protease inhibitors
• Combination Therapy
Based on route of administration, the hepatitis C treatment market has been segmented into the following:
• Oral
• Parenteral
Based on distribution channel, the hepatitis C treatment market has been segmented into the following:
• Retail Pharmacies
• Hospital Pharmacies
• Others
To view TOC of this report is available upon request @
Increase in prevalence of hepatitis C infection and liver cirrhosis expected to fuel the growth of Hepatitis C treatment market. According to the World Health Organization (WHO), globally there are 80 Mn people suffers from chronic hepatitis C virus, in that approximately 700,000 will die each year as a result of the infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as U.S. Food and Drug Administration are some strategies followed by various companies to increase their market share in global hepatitis C treatment market. For instance, in July 2011, Merck MSD, inked an agreement with Roche for the marketing approvals of Victreli (Boceprevir) triple combination therapy with peginterferon alfa and ribavirin (peg/riba). In addition, in August 2011, Vertex Pharmaceuticals Incorporated announced that Health Canada approved its Incivektm (Telaprevir) tablets for people with genotype 1 chronic hepatitis C with compensated liver disease. In January 2014, European Commission (EC) granted marketing authorization for Gilead’s Sovaldi (Sofosbuvir) to treat chronic hepatitis C infection.
Need more information about this report @
Geographically, the hepatitis C treatment market has been segmented into following regions Viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global hepatitis C treatment market followed by Europe and Asia-Pacific. Increase in prevalence of hepatitis C infection (according to Centres for Disease Prevention and Control (CDC), approximately 2.7-3.9 Mn people in the United States are chronically infected with hepatitis C Virus), rise in the awareness among the key stakeholders towards the use of novel products and technologies to treat the hepatitis C, and increase in research and development activities are the key factors bolster the hepatitis C treatment market in North America region. Europe holds a key share in hepatitis C treatment market owing to increase in prevalence of Hepatitis C infection (according to European centre for Disease Prevention and Control approximately 5.9 Mn people are suffering from HCV infection), rise in the geriatric population, change in the lifestyle, people involving in the unprotected sexual intercourse, and increase in the research and development activities might boost the hepatitis C treatment market in Europe region. Asia-Pacific hepatitis C treatment market growth is attributed to increase in the prevalence of hepatitis C infection, rise in the population in Asia-Pacific region, and increase in the healthcare infrastructure. The Middle East & Africa region has high prevalence of HCV infection majorly in Egypt that is approximately 8434 prevalent cases per 100,000 people.
Some of the players in Hepatitis C treatment market are GlaxoSmithKline, plc. (U.K.), Bristol-Myers Squibb (U.S), F. Hoffmann- La Roche Ltd. (Switzerland), Merck & Co, Inc. (U.S),  Johnson & Johnson Services, Inc. (U.S.), Gilead Sciences (U.S.), AbbVie Inc. (U.S.), Vertex Pharmaceuticals Inc. (U.S.), and Kadmon Holdings, Inc. (U.S.) to name a few.
About Precision Business Insights
Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.
Contact to Precision Business Insights,
Kemp House,
152 – 160 City Road,
London EC1V 2NX
Toll Free (US): +1-866-598-1553
Website @
Designed by
Powered by
%d bloggers like this: